<unk> , sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. It combines<unk>  and<unk> . It is more than 90% effective for hepatitis C genotypes one through six. It also works for hepatitis C in those who also have cirrhosis or HIV/AIDS. It is taken by mouth. In March 2020,<unk>  was approved for use in the United States to treat hepatitis C virus (HCV) in children ages six years and older or weighing at least 37 pounds (17 kilograms) with any of the six HCV genotypes—or strains—without cirrhosis (liver disease) or with mild cirrhosis.<unk>  in combination with ribavirin is indicated for the treatment of children six years and older or weighing at least 37 pounds with severe cirrhosis. The combination is generally well tolerated. Common side effects include headaches, fatigue, trouble sleeping, and nausea. The combination has not been studied in pregnant women or during breastfeeding. Greater care is required in those who are also infected with hepatitis B.<unk>  works by blocking the NS5B protein and<unk>  works by blocking the NS5A protein.<unk>  was approved for medical use in the United States and in Europe in 2016. It is on the World Health Organization's List of Essential Medicines.
Sofosbuvir/velpatasvir
Atazanavir/ritonavir
Ombitasvir/paritaprevir/ritonavir
Atazanavir/cobicistat
Abacavir/lamivudine
Ledipasvir/sofosbuvir
Darunavir/cobicistat
Abacavir/lamivudine/zidovudine